Moderna, Inc. (MRNA) · Nov 6, 2026 · Earnings
Beat — Q3 revenue $1.313B vs approximately $0.89B consensus
Moderna’s earnings sharply beat expectations as COVID sales drove a revenue surge and management raised 2026 growth guidance.
Moderna is transitioning from a COVID-heavy business toward a broader respiratory and oncology portfolio while cutting spending and preserving cash. The prior setup already called for a seasonally strong third quarter and up to 10% full-year revenue growth, but the published Q3 consensus was roughly $0.89 billion of revenue, with analysts expecting a loss; the quarter landed far above that bar.
The quarter was a clear operating beat, not just a narrative win. Revenue reached $1.313 billion, up 29% year over year, versus approximately $0.89 billion of published consensus, while diluted EPS was $0.38 versus a year-ago loss of $0.51. The upside was driven primarily by higher international COVID vaccine sales and government-partnership deliveries, so it validates near-term commercial execution but does not yet prove that the newer flu, RSV or oncology products are carrying the business. 〔0〕
| Q3 2026 | Q3 2025 | External / prior | |
|---|---|---|---|
| Total revenue (Financial results) | $1.313B (+29%) | $1.016B | ~$0.89B consensus |
| Diluted EPS (Financial results) | $0.38 | $(0.51) | |
| R&D expense (Financial results) | $583M (-27%) | $801M | |
| FY26 revenue growth (Outlook) | 15%-25% | Up to 10% prior outlook | |
| FY26 R&D expense (Outlook) | $2.7B | ~$2.9B prior outlook | |
| Year-end cash and investments (Outlook) | $8.1B-$8.3B | $4.7B-$5.2B prior outlook |
Management materially raised the business outlook. Full-year revenue growth is now expected at 15%-25%, versus the previous ceiling of 10%, while planned R&D falls to about $2.7 billion from $2.9 billion. That combination is better than the market was prepared for and strengthens the near-term transition story.
The balance-sheet improvement is real but partly financing-driven. Moderna ended September with $8.0 billion of cash and investments, and raised its year-end outlook to $8.1-$8.3 billion, but the quarter’s improvement relied heavily on approximately $2.6 billion of net convertible-note proceeds. That gives the company more room to fund oncology and meet debt obligations, yet it also adds leverage and means the cash upgrade is not solely the result of self-funded operations.
The pipeline adds support, but the quarter is still mainly a respiratory-sales story. Intismeran’s positive melanoma Phase 3 data strengthen Moderna’s longer-term diversification case, while the norovirus program failed to meet the early-success bar and will not add a cohort this season. The oncology opportunity is therefore advancing, but it remains dependent on regulatory submissions and eventual commercialization rather than current revenue.
Bottom line: This is a substantial beat that improves Moderna’s near-term revenue and cost-control story, with guidance raised well beyond the prior framework. It matters because execution exceeded a low bar by a wide margin, though the upside remains concentrated in seasonal COVID demand and partly supported by new debt financing.
Intismeran regulatory submissions and additional pipeline readouts
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!